Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,054 result(s) found for: Prior Placebo. Displaying page 8 of 353.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2004-003913-18 Sponsor Protocol Number: CSAB378A2201 Start Date*: 2005-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of SAB378 (15 mg t.i.d.) administered orally for 4 weeks to patients with posth...
    Medical condition: Postherpetic neuralgia (PHN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001580-22 Sponsor Protocol Number: 062 Start Date*: 2004-12-21
    Sponsor Name:MSD SHARP & DOHME GMBH
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sito...
    Medical condition: Homozygous Sitosterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-006192-13 Sponsor Protocol Number: C200-006 Start Date*: 2006-06-22
    Sponsor Name:Actelion Pharmaceuticals US, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SI...
    Medical condition: Pulmonary Arterial Hypertension (PAH) is a condition that is characterized by increased pulmonary arterial pressure and vascular resistance that can lead to right ventricular failure and death.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004935-22 Sponsor Protocol Number: TA-8995-303 Start Date*: 2020-10-01
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination with Ezetimibe in Participants with Mild Dyslipidemia
    Medical condition: mild dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002763-18 Sponsor Protocol Number: HZNP-TEP-301 Start Date*: 2018-02-22
    Sponsor Name:Horizon Therapeutics USA, Inc.
    Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial)
    Medical condition: Active Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003034-27 Sponsor Protocol Number: BN29552 Start Date*: 2016-07-13
    Sponsor Name:Roche Farma, S.A en nombre de F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODOMAL-TO-MILD ALZHEIMER?S DISEASE
    Medical condition: Alzheimer?s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) HU (Completed) PT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) BE (Prematurely Ended) DK (Completed) AT (Prematurely Ended) SI (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) BG (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014296-40 Sponsor Protocol Number: A3921032 Start Date*: 2009-11-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUA...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IE (Completed) BE (Completed) FR (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001515-29 Sponsor Protocol Number: 11492A Start Date*: 2006-07-10
    Sponsor Name:H. Lundbeck A/S
    Full Title: Double-blind, randomised, placebo-controlled study comparing the efficacy and safety of two fixed dosages of a novel antidepressant compound to that of placebo in patients with Major Depressive Dis...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) ES (Completed) AT (Completed) SK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001049-38 Sponsor Protocol Number: CLNP023A2301 Start Date*: 2020-12-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) NO (Completed) FI (Completed) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) SI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002536-67 Sponsor Protocol Number: ISIS678354-CS3 Start Date*: 2021-04-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001662-11 Sponsor Protocol Number: CINC424J12301 Start Date*: 2020-05-05
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID)
    Medical condition: COVID-19 associated cytokine storm
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001819-24 Sponsor Protocol Number: EFC16819 Start Date*: 2021-04-29
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) DK (Completed) HU (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002006-27 Sponsor Protocol Number: CKJX839B12302 Start Date*: 2021-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease...
    Medical condition: Atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005153-39 Sponsor Protocol Number: LX4211.1-310-T1DM Start Date*: 2015-04-28
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Typ...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) AT (Completed) ES (Completed) LT (Completed) DE (Completed) GB (Completed) HU (Completed) BE (Completed) SE (Completed) NL (Completed) PL (Completed) BG (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005844-47 Sponsor Protocol Number: D6580C00010 Start Date*: 2021-05-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants wit...
    Medical condition: Heart Failure with Left Ventricular Ejection Fraction > 40%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed) CZ (Completed) DK (Completed) BG (Completed) FR (Completed) HU (Completed) PL (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022382-10 Sponsor Protocol Number: CCX114151 Start Date*: 2011-01-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease
    Medical condition: Subjects with Moderately-to-Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) CZ (Completed) SE (Prematurely Ended) NO (Completed) BE (Completed) DK (Completed) HU (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-014858-15 Sponsor Protocol Number: TRC112765 Start Date*: 2010-10-27
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR),...
    Medical condition: chemotherapy induced thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IE (Completed) GR (Completed) FI (Completed) HU (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005476-27 Sponsor Protocol Number: CACZ885G2305 Start Date*: 2009-05-14
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio randomizado, doble ciego, controlado con placebo, a dosis única para evaluar la eficacia inicial de canakinumab (ACZ885) respecto a los Criterios ACR 30 Pediátricos Adaptados en pacientes c...
    Medical condition: Artritis idiopática juvenil sistémica y manifestaciones sistémicas activas.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NO (Ongoing) FR (Completed) HU (Completed) DE (Completed) BE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-003752-30 Sponsor Protocol Number: 088 Start Date*: 2008-11-27
    Sponsor Name:Merck & Co., Inc
    Full Title: Estudio internacional, multicéntrico, aleatorizado, doble ciego de Vorinostat (MK-0683) o placebo en combinación con bortezomib en pacientes con mieloma multiple An International, Multicenter, Ran...
    Medical condition: mieloma múltiple multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FR (Completed) AT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Prematurely Ended) IT (Completed) BG (Prematurely Ended) GB (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002742-20 Sponsor Protocol Number: CL2-16257-101 Start Date*: 2013-03-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction A...
    Medical condition: Heart failure with preserved left ventricular ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) IT (Completed) DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) AT (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 01:11:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA